利培酮合并丁螺环酮治疗精神分裂症对照研究

目的探讨利培酮合并丁螺环酮治疗精神分裂症的临床疗效及副反应。方法将72例精神分裂症患者随机分为研究组（利培酮合并丁螺环酮治疗）36例和对照组（利培酮单用治疗）36例,疗程均为8周,采用阳性和阴性症状量表（PANSS）评定疗效,采用副反应量表（TESS）及实验室检查评定各种副反应。结果研究组第1周末PANSS平均减分率较对照组降低更明显（P〈0．05）,其他各周末PANSS平均减分率降低相当。两组的副反应发生率分别为研究组11．11％,对照组22．22％,严重程度大多数为轻度,少数为中度。利培酮总用量研究组较对照组少。结论利培酮合并丁螺环酮治疗精神分裂症起效快,可减少利培酮药物反应,降低其治疗量。     

利培酮治疗精神分裂症阴性症状对照研究

以利培酮和舒必利对照治疗以阴性症状为主的精神分裂症 ,观察其疗效和不良反应 ,报告如下。1　对象和方法选取符合中国精神疾病分类方案与诊断标准第 2版修订本诊断标准的以阴性症状为主的精神分裂症住院患者 ,简明精神病评定量表 (BPRS)评分 >35分 ;阴性症状按湖南精神病协会制订的阴性症状量表 [HEN(Ⅲ ) ]评定标准 ,病人具备 6项中的 2项 ,每项大于 2分。共 4 4例 ,随机分为两组。利培酮组 2 2例 ,男 12例 ,女 10例 ;年龄 17～ 6 5岁 ,平均(32 5± 9 2 )岁 ;病程 0 5～ 11年 ,平均 (5 5± 1 5 )年。舒必利组 2 2例 ,男 11例 ,女 11…     

利培酮联合低剂量安非他酮对精神分裂症患者阴性症状的疗效

目的本研究探讨安非他酮对精神分裂症患者阴性症状的干预效果。方法以某精神病医院住院精神分裂症患者80例为研究对象,研究组在原有利培酮剂量不变的基础上,联用安非他酮150mg/d,对照组原有利培酮剂量不变。两组患者分别于治疗前、治疗后8周后分别接受量表评估。采用阳性与阴性症状量表(PANSS)评定治疗前后患者精神病性症状的变化;以副反应反应量表(TESS)及化验和辅助检查进行安全性评估。结果 PANSS总分及阴性症状分量表分差异有统计学意义(P0.05)。组间比较以上评估差异有统计学意义(P0.05),研究组优于对照组。结论利培酮联合低剂量安非他酮可以改善精神分裂症患者的阴性症状。     

利培酮合并丁螺环酮治疗偏执型精神分裂症的疗效对比分析

丁螺环酮为五羟色胺1A（5-HT1A）受体激动剂,临床上主要用于治疗焦虑障碍.为研究利培酮合并丁螺环酮治疗偏执型精神分裂症的疗效,并与单独利培酮的治疗进行比较,现将结果报告如下：     

文拉法辛联合利培酮治疗精神分裂症阴性症状的疗效观察

有报道利培酮和多种抗抑郁剂均对精神分裂症阴性症状有一定疗效。本文采用文拉法辛联合利培酮治疗精神分裂症的阴性症状,并与单独利培酮治疗进行疗效及不良反应比较,现将结果报道于后。     

利培酮联合氯氮平治疗精神分裂症阴性症状的对照观察

本组试用利培酮联合氯氮平治疗 2 0例以阴性症状为主的精神分裂症并与单独利培酮和单独氯氮平治疗比较。现将结果报道于后。1　对象和方法1.1　对象　均符合ＣＣＭＤ - 2 -Ｒ中精神分裂症的诊断标准 ,且以阴性症状为主者。年龄、性别不限 ,并随机分成三个组 :①利培酮组 ,其中男 12例 ,女 8例 ;年龄 2 0～ 4 8岁 ,平均年龄 (32 .4± 8.5 )岁 ;平均病期6 .3年。②氯氮平组 ,其中男 9例 ,女 11例 ;年龄 19～ 5 6岁 ,平均年龄 (34.5± 11.4 )岁 ;平均病期 7.8年。③利培酮联合氯氮平组 (以下简称联合组 ) ,其中男 13例 ,女 7例 ;平均年龄 (36 .…     

丁螺环酮联合氨磺必利对精神分裂症阴性症状和认知功能的影响

目的 探讨丁螺环酮联合氨磺必利治疗精神分裂症（SP）阴性症状的效果及对认知功能的影响。方法 选取2019年1月～2022年10月医院收治的82例SP阴性症状患者,依照随机数表法分为对照组和观察组,各41例。对照组采用氨磺必利治疗,观察组采用氨磺必利+丁螺环酮治疗,两组均治疗12周。对比阳性与阴性症状量表（PANSS）评分、阴性症状量表（SANS）评分、临床疗效,精神分裂症认知功能成套测验共识版（MCCB）、个人与社会量表（PSP）评分、神经功能因子S100β蛋白（S100β）、髓鞘碱性蛋白（MBP）及不良反应。结果 观察组治疗后PANSS评分、SANS评分均低于对照组（P均<0.05）。观察组治疗后疗效优于对照组（P<0.05）。观察组治疗后MCCB评分、PSP评分高于对照组（P均<0.05）。观察组治疗后S100β、MBP水平低于对照组（P均<0.05）。观察组未出现明显不良反应。结论 SP阴性症状患者用氨磺必利联合丁螺环酮治疗可缓解临床症状、提高临床疗效、改善认知功能和社会功能,调节神经功能因子水平。     

利培酮和氯氮平治疗精神分裂症阴性症状的对照研究

为比较利培酮与氯氮平对精神分裂症阴性症状的疗效与副反应,应用利培酮与氯氮平治疗以阴性症状为主的精神分裂症各22例,疗程12周,用BPRS、SANS、TESS评定疗效和副反应。结果,利培酮组SANS减分率51.47%,氯氮平组减分率52.36%。提示：利培酮与氯氮平对治疗精神分裂症阴性症状均有一定效果,二对阴性症状疗效无显性差异。利培酮副作用发生率较氯氮平少而轻,安全性高,依从性好。     

利培酮和氯氮平对精神分裂症阴性症状的疗效及不良反应比较

目的比较利培酮与氯氮平对精神分裂症阴性症状的疗效和不良反应。方法应用利培酮和氯氮平治疗精神分裂症各２０例，其阴性症状评定量表评分≥６５分者入组。用阴性症状评定量表（ＳＡＮＳ）评定疗效，用副反应量表（ＴＥＳＳ）评定药物不良反应。结果利培酮和氯氮平对精神分裂症阴性症状的疗效相当，起效时间为２周。两药的副反应不同，利培酮多见锥体外系反应，而氯氮平多见心动过速、嗜睡、流涎、便秘等。结论利培酮对精神分裂症阴性症状有效、疗效与氯氮平相当。     

利培酮联合帕罗西汀治疗慢性精神分裂症阴性症状

目的:探讨利培酮联合帕罗西汀治疗慢性精神分裂症阴性症状的临床疗效以及安全性.方法:将126例以阴性症状为主的慢性精神分裂症住院患者随机分为研究组(利培酮联合帕罗西汀治疗)和对照组(单用利培酮治疗),疗程12周,采用阳性和阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效和安全性. 结果:治疗后两组PANSS评分均较治疗前有显著降低(P＜0.05).治疗后4、8、12周末,研究组阴性因子分及情感迟钝、情感退缩、情感交流障碍及社会退缩因子分均显著低于对照组,差异具有统计学意义(P＜0.05或P＜0.01).两组不良反应均为轻至中度. 结论:利培酮联合帕罗西汀较单用利培酮治疗慢性精神分裂症阴性症状具有起效更快、疗效更好、依从性好的特点.     

利培酮合并舍曲林治疗精神分裂症阴性症状的研究

目的探讨舍曲林合并利培酮治疗精神分裂症阴性症状的疗效及安全性。方法将86例以阴性症状为主的住院精神分裂症患者随机分为研究组(舍曲林 利培酮)和对照组(利培酮 安慰剂)。在治疗前及治疗后4、8、12周,用阳性与阴性症状量表(PANSS)、不良反应量表(TESS)评定疗效和安全性。结果治疗后8、12周,两组PANSS总分、阴性因子分比较差异有统计学意义(P<0.05)。研究组阴性因子各项症状评分低于对照组,差异有统计学意义(P<0.05或P<0.01)。而两组TESS评定无统计学意义(P>0.05)。结论舍曲林合并利培酮治疗精神分裂症阴性症状安全有效,副作用少。     

艾司西肽普兰联合利培酮对精神分裂症阴性症状疗效和安全性

目的 观察艾司西肽普兰辅助治疗精神分裂症患者阴性症状的疗效及安全性。方法 采用随机双盲对照研究方法。将我院86例住院精神分裂症患者分为两组,排除脱落人数后最终人数为：研究组利培酮联合艾司西肽普兰组39例;对照组利培酮联合安慰剂组41例。分别于基线及治疗第4、8、12周末采用阳性和阴性症状量表（PANSS）、阴性症状量表（SANS）、个人和社会功能量表（PSP）评估疗效,不良反应量表（TESS）评估安全性。结果 两组中PANSS总分、阴性因子总分、SANS总分于治疗第4周末开始均低于治疗前,两组中PSP总分于治疗第4周开始均高于治疗前（P<0.01）;在第8周末及第12周末利培酮联合艾司西酞普兰组PANSS阴性因子总分、SANS总分、分量表综合评价分均低于对照组（P<0.01）,PSP总分均高于对照组（P<0.01）;利培酮联合艾司西酞普兰组与利培酮联合安慰剂组PANSS阴性因子总分、SANS总分、PSP总分组间效应、时间主效应、交互效应均有统计学意义（P<0.01或P<0.05）。两组间不良反应差异无统计学意义（P>0.05）。结论 艾司西酞普兰对治...     

利培酮合用米氮平治疗精神分裂症阴性症状的研究

目的　探讨米氮平治疗精神分裂症阴性症状的疗效和安全性。方法　将 86例以阴性症状为主的住院精神分裂症患者随机分为研究组对对照组 ,分别给予利培酮合用米氮平及单用利培酮治疗 ,疗程 12周 ,用PANSS、TESS评定疗效和安全性。结果　疗后 4周两组PANSS总分、阳性因子分、阴性因子分及 8、12周末两组PANSS总分和各因子分与疗前比较差异有显著性 (P <0 0 5或P <0 0 1)。治疗后 8、12周两组间比较PANSS总分及阴性因子分差异有显著性 (P <0 0 5或P <0 0 1)。结论　米氮平治疗精神分裂症阴性症状疗效较好 ,副作用少。     

Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia

The efficacy of flupentixol and risperidone were compared in a randomized double-blind study in 153 chronic schizophrenic patients. Flupentixol showed to be not inferior to risperidone concerning schizophrenic negative symptoms at week 8, 16 and 24. Positive symptoms and general psychopathology improved comparably, too. There was a trend in favor of flupentixol concerning the improvement of depressive symptoms and a trend in favor of risperidone concerning the improvement of preexisting parkinsonian symptoms. The study data justify to regard flupentixol as a "partial atypical" antipsychotic.     

Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms

The study investigated the non-inferiority of flupentixol compared to risperidone in the treatment of negative symptoms. In addition, the effects of flupentixol on mood and cognitive symptoms were explored. In a randomized, double-blind multicenter study, 144 non-acute schizophrenia patients with predominant negative symptoms were treated with a flexible dose of either flupentixol (4-12 mg/d) or risperidone (2-6 mg/d) for up to 25 weeks. In addition to a non-inferiority analysis, a principal component analysis (PCA) of the PANSS was performed post hoc. Regarding negative symptoms, flupentixol proved to be non-inferior to risperidone. Both drugs improved depressed mood with effect sizes favoring flupentixol. PCA suggested a five-factor structure. Effect sizes for the cognitive factor were up to 0.74 for flupentixol and up to 0.80 for risperidone. EPS scores were rather low and Parkinsonism improved in both groups, but anticholinergic drugs were prescribed significantly more frequently in the flupentixol group, which generally showed significantly more adverse events. Results indicate that the 1st generation antipsychotic flupentixol improves negative, affective and cognitive symptoms in chronic schizophrenia comparable to risperidone. Further studies should confirm the latter using neuropsychological performance tests and should investigate whether tolerability improves with a markedly lower dose range.     

D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia

BACKGROUND: D-Cycloserine, a partial agonist at the glycine recognition site of the NMDA receptor has previously been shown to improve negative symptoms when added to conventional antipsychotics and to worsen negative symptoms when added to clozapine. The purpose of this study was to examine the effects of D-cycloserine when added to risperidone on negative symptoms of schizophrenia. METHOD: Ten patients with schizophrenia who were treated with risperidone completed consecutive two week trials of placebo and four doses of D-cycloserine. Clinical assessments were videotaped and were scored by a rater who was blind to temporal sequence. RESULTS: D-Cycloserine at a dose of 50mg/day was associated with significant reduction in negative symptoms (mean=10%). Ratings of depression, extrapyramidal side effects, and cognitive function were unchanged. Serum concentrations of glutamate and serine increased significantly on this dose of D-cycloserine. CONCLUSIONS: This preliminary study suggests that combination of D-cycloserine, 50mg/day, with risperidone may improve negative symptoms of schizophrenia over a narrow dose range. The degree of improvement appears to be intermediate between improvement of negative symptoms observed with combination of D-cycloserine with conventional antipsychotics and worsening of negative symptoms observed with combination of D-cycloserine with clozapine in previous trials of identical design.     

利培酮与舒必利治疗精神分裂症阴性症状Meta分析

目的：采用Meta分析方法比较利培酮与舒必利治疗精神分裂症阴性症状的临床疗效。方法：将利培酮与舒必利治疗精神分裂症阴性症状的16个中文的随机对照研究进行再分析。结果：16个研究的合并效应量（WMD）为-0．58（-1．37，0．21；P〉0．05）。阳性与阴性症状量表（PANSS）阴性因子（N）亚组的WMD为-0．84（-1．91，0．24；P〉0．05）；阴性症状评定量表（SANS）亚组的WMD为0．19，（-0．77，1．15；P〉0．05）。结论：利培酮与舒必利对精神分裂症阴性症状的疗效无显著差别。     

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms

Evidence suggests that neurocognitive impairment is a key factor in the pathology of schizophrenia and is linked with the negative symptoms of the disease. In this study the effects of the atypical antipsychotics quetiapine and risperidone on cognitive function in patients with schizophrenia and with predominantly negative symptoms were compared. Patients were randomly assigned to double-blind treatment with quetiapine or risperidone for 12 weeks. Cognitive function was assessed at baseline, Week 6 and Week 12. Efficacy was assessed using the Positive and Negative Syndrome Scale (PANSS) and the Scale for the Assessment of Negative Symptoms (SANS) at baseline, Week 6 and Week 12. Extrapyramidal side-effects were assessed each week using the Simpson-Angus Scale (SAS), adverse events were recorded as additional indicators of tolerability throughout the trial. In total, 44 patients were enrolled in the study. Data from the 34 patients who completed cognitive assessments at two or more time points out of three (baseline, Week 6 and Week 12) are analysed here. Quetiapine improved significantly global cognitive index z-scores at both Week 6 (p < 0.001 vs. baseline) and Week 12 (p < 0.01 vs. baseline), whereas risperidone improved significantly global cognitive index z-scores at Week 12 (p < 0.05). Between-group comparisons at Week 6 showed significantly greater improvements in working memory and verbal memory with quetiapine than risperidone (p < 0.05) and a significantly greater improvement in reaction quality/attention with quetiapine than risperidone at Week 12 (p<0.05). Quetiapine and risperidone produced significant improvements from baseline in PANSS total (p<0.001) and subscale scores at Week 12. Significant improvements in SANS total score were also seen in both the quetiapine (p < 0.001) and risperidone (p < 0.01) groups at Week 12 compared with baseline. SAS scores, measuring the incidence of extrapyramidal side-effects, were higher in patients receiving risperidone compared with those receiving quetiapine, and significant differences were seen at Weeks 3, 4, 5 and 7. Both quetiapine and risperidone improved cognition according to changes in cognitive index scores from baseline to Week 12. These results suggest that quetiapine and risperidone provide valuable treatment options for patients with schizophrenia with predominantly negative symptoms. Also, the improvements in cognition following treatment with quetiapine and risperidone may enhance long-term outcomes for these patients.